BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 10820353)

  • 21. Biochemical failure and the temporal kinetics of prostate-specific antigen after radiation therapy with androgen deprivation.
    Buyyounouski MK; Hanlon AL; Horwitz EM; Uzzo RG; Pollack A
    Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1291-8. PubMed ID: 15817330
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PSA kinetics after prostate brachytherapy: PSA bounce phenomenon and its implications for PSA doubling time.
    Ciezki JP; Reddy CA; Garcia J; Angermeier K; Ulchaker J; Mahadevan A; Chehade N; Altman A; Klein EA
    Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):512-7. PubMed ID: 16213667
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biochemical failure as a determinant of distant metastasis and death in prostate cancer treated with radiotherapy.
    Pollack A; Hanlon AL; Movsas B; Hanks GE; Uzzo R; Horwitz EM
    Int J Radiat Oncol Biol Phys; 2003 Sep; 57(1):19-23. PubMed ID: 12909210
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: the relationship between nadir level and disease-free survival.
    Lee WR; Hanlon AL; Hanks GE
    J Urol; 1996 Aug; 156(2 Pt 1):450-3. PubMed ID: 8683700
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Definitions of biochemical failure in prostate cancer following radiation therapy.
    Taylor JM; Griffith KA; Sandler HM
    Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1212-9. PubMed ID: 11483331
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of biochemical failure definitions for permanent prostate brachytherapy.
    Kuban DA; Levy LB; Potters L; Beyer DC; Blasko JC; Moran BJ; Ciezki JP; Zietman AL; Zelefsky MJ; Pisansky TM; Elshaikh M; Horwitz EM
    Int J Radiat Oncol Biol Phys; 2006 Aug; 65(5):1487-93. PubMed ID: 16750326
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results.
    Demanes DJ; Rodriguez RR; Schour L; Brandt D; Altieri G
    Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1306-16. PubMed ID: 15817332
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Changes in biochemical disease-free survival rates as a result of adoption of the consensus conference definition in patients with clinically localized prostate cancer treated with external-beam radiotherapy.
    Ennis RD; Malyszko BK; Heitjan DF; Rubin MA; O'Toole KM; Schiff PB
    Int J Radiat Oncol Biol Phys; 1998 Jun; 41(3):511-7. PubMed ID: 9635696
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis.
    Ray ME; Thames HD; Levy LB; Horwitz EM; Kupelian PA; Martinez AA; Michalski JM; Pisansky TM; Shipley WU; Zelefsky MJ; Zietman AL; Kuban DA
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1140-50. PubMed ID: 16198506
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Matched-pair analysis of conformal high-dose-rate brachytherapy boost versus external-beam radiation therapy alone for locally advanced prostate cancer.
    Kestin LL; Martinez AA; Stromberg JS; Edmundson GK; Gustafson GS; Brabbins DS; Chen PY; Vicini FA
    J Clin Oncol; 2000 Aug; 18(15):2869-80. PubMed ID: 10920135
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dose-response characteristics of low- and intermediate-risk prostate cancer treated with external beam radiotherapy.
    Cheung R; Tucker SL; Lee AK; de Crevoisier R; Dong L; Kamat A; Pisters L; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):993-1002. PubMed ID: 15752878
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of conformal high-dose rate brachytherapy for management of patients with prostate cancer: optimizing dose escalation.
    Vicini FA; Kestin LL; Martinez AA
    Tech Urol; 2000 Jun; 6(2):135-45. PubMed ID: 10798815
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prostate biopsy status and PSA nadir level as early surrogates for treatment failure: analysis of a prostate cancer randomized radiation dose escalation trial.
    Pollack A; Zagars GK; Antolak JA; Kuban DA; Rosen II
    Int J Radiat Oncol Biol Phys; 2002 Nov; 54(3):677-85. PubMed ID: 12377318
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is supplemental external beam radiation therapy necessary for patients with higher risk prostate cancer treated with 103Pd? Results of two prospective randomized trials.
    Merrick GS; Wallner KE; Galbreath RW; Butler WM; Fiano R; Orio PF; Adamovich E
    Brachytherapy; 2015; 14(5):677-85. PubMed ID: 26051802
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of obesity on prostate-specific antigen recurrence after radiation therapy for localized prostate cancer as measured by the 2006 Radiation Therapy Oncology Group-American Society for Therapeutic Radiation and Oncology (RTOG-ASTRO) Phoenix consensus definition.
    Stroup SP; Cullen J; Auge BK; L'Esperance JO; Kang SK
    Cancer; 2007 Sep; 110(5):1003-9. PubMed ID: 17614338
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcome and predictive factors for patients with Gleason score 7 prostate carcinoma treated with three-dimensional conformal external beam radiation therapy.
    Anderson PR; Hanlon AL; Horwitz E; Pinover W; Hanks GE
    Cancer; 2000 Dec; 89(12):2565-9. PubMed ID: 11135217
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemical disease-free survival in localized carcinoma of prostate treated with external beam irradiation: comparison of American Society of Therapeutic Radiology and Oncology Consensus or 1 ng/mL as endpoint.
    Perez CA; Michalski JM; Lockett MA
    Int J Radiat Oncol Biol Phys; 2001 Apr; 49(5):1287-96. PubMed ID: 11286836
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prostate-specific antigen (PSA) bounce and other fluctuations: which biochemical relapse definition is least prone to PSA false calls? An analysis of 2030 men treated for prostate cancer with external beam or brachytherapy with or without adjuvant androgen deprivation therapy.
    Pickles T;
    Int J Radiat Oncol Biol Phys; 2006 Apr; 64(5):1355-9. PubMed ID: 16406391
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of percent positive prostate biopsies and perineural invasion with biochemical outcome after external beam radiotherapy for localized prostate cancer.
    Wong WW; Schild SE; Vora SA; Halyard MY
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):24-9. PubMed ID: 15337536
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Variable definitions influence the reporting of biochemical failure rates.
    Cherullo EE; Ponsky LE; Goyal KK; Pasquallotto F; Zippe CD
    Prostate Cancer Prostatic Dis; 2002; 5(1):54-8. PubMed ID: 15195131
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.